Pioneering the discovery and development of selective translation regulators to harness the body’s ability to fight cancer.
eFFECTOR Therapeutics is pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer and other serious diseases.
eFFECTOR is built on significant chemical and biological expertise. Through the fusion of these two disciplines, we can pharmaceutically control the regulation of messenger RNA (mRNA) translation. eFFECTOR believes that its expertise in these two disciplines gives the company a key advantage in the emerging field of selective translation regulator therapeutics.
eFFECTOR is passionate about using the best science to develop better medicines to treat cancer. Learn more about participating in one of our clinical trials.
11180 Roselle Street
San Diego, CA 92121